Sanofi

YTD

ALL

Why Robinhood?

You can watch Sanofi and buy or sell other stocks, ETFs, and their options commission-free!

About SNY

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the Biopharma segment, which comprises commercial operations and research, development and production activities relating to the specialty care, general medicines and vaccines franchises plus support and corporate functions, for all geographical territories.

CEO

Belén Garijo López

CEOBelén Garijo López

Employees

76,493

Employees76,493

Headquarters

Paris, Ile-de-France

HeadquartersParis, Ile-de-France

Founded

1994

Founded1994

Employees

76,493

Employees76,493

SNY Key Statistics

Market cap

105.20B

Market cap105.20B

Price-Earnings ratio

18.08

Price-Earnings ratio18.08

Dividend yield

4.06%

Dividend yield4.06%

Average volume

3.66M

Average volume3.66M

High today

$43.75

High today$43.75

Low today

$43.24

Low today$43.24

Open price

$43.50

Open price$43.50

Volume

2.66M

Volume2.66M

52 Week high

$52.68

52 Week high$52.68

52 Week low

$40.89

52 Week low$40.89

SNY News

Benzinga 1d

Sanofi Wins FDA Approval for Wearable Injector Form of Blood Cancer Drug

The approval makes Sarclisa Escena the first anticancer therapy that can be administered through both an on-body injector (OBI) and manual subcutaneous injectio...

TipRanks 1d

Sanofi’s iGlarLixi Diabetes Trial Nears Readout: What Investors Should Watch

Sanofi (SNYNF) announced an update on their ongoing clinical study. Unlock powerful investing tools and data-driven insights with TipRanks Premium for more con...

TipRanks 1d

Sanofi announces subcutaneous Sarclisa Escena approved in U.S.

The U.S. Food and Drug Administration has approved subcutaneous Sarclisa Escena in combination with standard-of-care regimens for the treatment of patients with...

Analyst ratings

57%

of 7 ratings

Buy

42.9%

Hold

57.1%

Sell

More SNY News

TipRanks 3d

Sanofi price target lowered to $49 from $52 at Morgan Stanley

Morgan Stanley analyst Sarita Kapila lowered the firm’s price target on Sanofi (SNY) to $49 from $52 and keeps an Equal Weight rating on the shares. Sanofi appe...

TipRanks 4d

Sanofi’s Nexviazyme Delivers Positive Phase 3 Results in Infantile-Onset Pompe Disease

Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions. Discover top stock picks and new invest...

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.